Kelyniam Global Inc. (OTCMKTS:KLYG) Stock Jumps After Strategic Licensing Agreement
Shares of Kelyniam Global Inc. (OTCMKTS:KLYG) closed higher on Wednesday after announcing a key strategic licensing agreement.
Market Stats
On Wednesday, KLYG stock jumped 10% to $0.11 with more than 818k shares, compared to its average volume of 58k shares. The stock has moved within a range of $0.0925 – 0.1800 after opening trading at $0.0.1390.
Kelyniam Global Signs Strategic Licensing Agreement with for marketing Hydroxyapatite Cranial Implant
Kelyniam Global, Inc. (OTCMKTS:KLYG) one of the industry leaders in manufacturing custom cranial PEEK (polyether ether ketone) implants, announced on December 22, 2021, about finalizing a strategic licensing agreement with Fin-ceramica faenza spa. The agreement is for the purpose of marketing Kelyniam Global’s hydroxyapatite patient specific implant.
The cutting edge CustomizedBone Service implant can be used in adults, as well as pediatric patients aged 7 and above. It is made using an extremely bio-compatible material, which has shown a reduced post-op infection incidence compared to titanium-based implants. The material is based on macro and micro porous Hydroxyapatite (HA), a major (70%) component of human bone. This bio-mimetic chemical composition combined with an enhanced interconnected porosity, is important when it comes to the perimetral osteointegration process.
Laura Reed, Kelyniam’s National Sales Director stated that Fin-ceramica’s unique implant is the ideal product for their company, especially due to the integrative properties of hydroxyapatite and the implant’s commercial success in Europe. Ross Bjella, Kelyniam’s CEO is equally thrilled to collaborated with a technology leading company like Fin-ceramica.
The implant is set to be distributed through the company’s active salesforce consisting of more than 50 representatives, from January 2022. Both PEEK and and hydroxyapatite products will be available.
Traders Corner
KLYG stock is trading below the 20-Day and 50-Day Moving averages of $0.1254 and $0.1433 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.1575.